Your company account is blocked and you cannot place orders. If you have questions, please contact your company administrator.

Ozoralizumab (anti-TNF-alpha&HSA) - Primary antibody, specific to TNF; ALB, INHIBITOR of TNF-alpha inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Features and benefitsView More
  • Host species: Human
  • Species reactivity(Reacts with): Human
  • Conjugation: Unconjugated
Item Number
Ab175623
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175623-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$79.90
Ab175623-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$379.90
Ab175623-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$989.90
Ab175623-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,589.90

Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameOzoralizumab (anti-TNF-alpha&HSA) - Primary antibody, specific to TNF; ALB
SynonymsATN-103 | APC1 antibody | APC1 protein antibody | Cachectin antibody | DIF antibody | Differentiation inducing factor antibody | Macrophage cytotoxic factor antibody | Tnf antibody | TNF superfamily member 2 antibody | TNF superfamily, member 2 antibody |
Specifications & PurityCarrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥90%(SDS-PAGE&SEC-HPLC), See COA
Host speciesHuman
SpecificityTNF; ALB
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionINHIBITOR of TNF-alpha inhibitor
Product Description

Ozoralizumab (anti-TNF-alpha&HSA) is an anti-TNFα humanized antibody. Ozoralizumab (anti-TNF-alpha&HSA) is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab (anti-TNF-alpha&HSA) can be used in research of arthritis.
Purity
≥90% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg

Product Properties

SDS-PAGE38.44 kDa
Purification MethodProtein A purified
FormLiquid
ConcentrationSee COA
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1167985-17-2

Associated Targets(Human)

TNF Tclin Tumor necrosis factor (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ALB Tchem Serum albumin (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
TNF Tclin TNF-alpha (1897 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences
TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

DailyMed: [1]


TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

DailyMed: [1]


TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

DailyMed: [1]


TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

DailyMed: [1]


PubMed: [1]


TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

DailyMed: [1]


TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

PubMed: [1]


TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

PubMed: [1]


TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

PubMed: [1]


TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

PubMed: [1]


TNF-alpha inhibitorINHIBITORALA1825TNF-alphaSINGLE PROTEINHomo sapiens

PubMed: [1]


Certificates

C of A & Other Certificates

Related Documents

References

1. Kratz F, Elsadek B.  (2012)  Clinical impact of serum proteins on drug delivery..  J Control Release,  161  (2): (429-45).  [PMID:22155554] [10.1021/op500134e]

Solution Calculators